| Primary Identifier | MGI:3620013 | Allele Type | Transgenic |
| Attribute String | Humanized sequence, Inserted expressed sequence | Gene | Tg(CTSG-PML/RARA)135Ley |
| Strain of Origin | Not Specified | Is Recombinase | false |
| Is Wild Type | false |
| description | This is one of 6 lines described in J:77881 that express this transgenic construct, and one of 3 whose combined phenotype is described in detail. Leukemia in mice with this transgene is a model for acute promyelocytic leukemia; see OMIM *102578: ACUTE PROMYELOCYTIC LEUKEMIA, INDUCER OF; PML |
| molecularNote | The functional cDNA coding sequence is derived from the breakpoint cluster region 1 (bcr-1) isoform transcript of the PML/RARA fusion gene resulting from the characteristic t(15;17)(q22;q11.2-q12) translocation associated with ~90% of human cases of acute promyelocytic leukemia (APML). Expression is targeted specifically to early myeloid-lineage cells by the promoter and 5' regulatory elements of the human cathepsin G gene. The protein product of the fusion gene retains the DNA binding, dimerization and retinoic acid binding domains of the wild-type retinoic acid receptor alpha (RARalpha) protein under control of the regulatory elements of the PML protein. Transgenic line 135 has integrated 4 copies of the transgene. Southern blot analysis of RT-PCR products demonstrates expression in bone marrow; expression in spleen is at the detection limit of RNase protection analysis. |
